Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression

Glioblastoma (GBM) is a highly aggressive form of brain cancer with a poor prognosis and limited treatment options. The ALK and c-MET inhibitor Crizotinib has demonstrated preclinical therapeutic potential for newly diagnosed GBM, although its efficacy is limited by poor penetration of the blood bra...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Molecular pharmaceutics 2023-12, Vol.20 (12), p.6140-6150
Hauptverfasser:	Pflug, Kathryn M, Lee, Dong W, Tripathi, Ashutosh, Bankaitis, Vytas A, Burgess, Kevin, Sitcheran, Raquel
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Brain Neoplasms - drug therapy Brain Neoplasms - pathology Cell Line, Tumor Crizotinib - pharmacology Crizotinib - therapeutic use Glioblastoma - drug therapy Glioma - drug therapy Glioma - pathology Humans Mice NF-kappa B NF-kappaB-Inducing Kinase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!